Mesothelioma Clinical Trials ALIMTA (pemetrexed) Plus Gemcitabine (Gemzar) for Patients with Malignant Pleural or Peritoneal Mesothelioma who have not had previous chemotherapy This study is currently recruiting patients. Sponsored by Eli Lilly and Company For more information:National Cancer Institute (NCI)   PURPOSE: The purposes of this study are to determine: 1) The safety of ALIMTA plus Gemcitabine and any side effects that might be associated with the combination of these two drugs. 2) Whether ALIMTA plus Gemcitabine can help patients with mesothelioma live longer. 3) Whether ALIMTA plus Gemcitabine can make the tumor smaller or disappear, and for how long. 4) To see if patients feel better while taking ALIMTA plus Gemcitabine. Condition Treatment or Intervention Mesothelioma  Drug: ALIMTA Plus Gemcitabine This is a Phase II test In Phase II clinical trials, the study drug or treatment is given to a larger group of people (100-300) to see if it is effective and to further evaluate its safety.   Study Type: Interventional Study Design: Treatment Ages Eligible for Study:  18 Years and above,  Genders Eligible for Study:  Both Criteria Inclusion Criteria: Diagnosis of mesothelioma that can be treated with chemotherapy Have received no prior chemotherapy for mesothelioma Have at least one measurable lesion Have an adequate performance status Sign an informed consent Exclusion Criteria: Previous treatment with chemotherapy for mesothelioma Treatment with an investigational drug within the last 30 days, previously completed or withdrawn from this study or any other study investigating ALIMTA Treatment with radiation therapy within the last 4 weeks Brain metastasis that is uncontrolled Active infection or other serious condition